Thrombotic thrombocytopenic purpura (TTP) is a critical condition marked by the obstruction of small blood vessels in the brain. This is often due to the suppression of the enzyme ADAMTS13, which typically cleaves the blood protein known as Von Willebrand Factor into smaller fragments. TTP is identified by microthrombi, which are minute clots formed by platelets, leading to a deficiency in platelets. Symptoms also include fever, kidney issues, and neurological symptoms such as speech difficulties, vision loss, and seizures. Although TTP is rare, affecting 3.7 individuals per million annually, advancements like plasma exchange have significantly lowered the mortality rate from 90% to between 10% and 20% for those who receive immediate treatment. Certain medications, including the antiplatelet drug clopidogrel (Plavix), have been linked to TTP.